Dentsply Sirona (XRAY) Misses Q4 EPS by 2c, Revenues Beat; Offers FY20 EPS/Revenue Outlook

Dentsply Sirona (NASDAQ: XRAY) reported Q4 EPS of $0.73, $0.02 worse than the analyst estimate of $0.75. Revenue for the quarter came in at $1.11 billion versus the consensus estimate of $1.09 billion.

• Reported Q419 revenues of $1,112 million, up 4.9% as compared to prior year and up 8.4% on an internal sales growth basis
• Q419 EPS of $0.46 vs. $0.01 in Q418. Q419 non-GAAP EPS of $0.73 vs. $0.58 in Q418
• Q419 operating income increased 67% YoY to $137 million and operating income margin was 12.4%. Q419 non-GAAP operating income grew 26% YoY to $222 million and non-GAAP operating income margin was 20.2%
• Q419 cash flow from operations of $299 million, up 48% as compared to prior year
• Company announces FY20 non-GAAP EPS Guidance Range of $2.55 to $2.80

Don Casey, Chief Executive Officer, commented; “The fourth quarter of 2019 capped off a year of strong financial performance. Our results today clearly indicate that our restructuring plan is delivering on its promise, as evidenced by the uptick in innovation in 2019, our reenergized sales teams, and benefits stemming from our portfolio shaping activities. In the fourth quarter and for the full year, we delivered strong revenue growth, driven by robust increases in the Technologies & Equipment segment, and in particular, driven by our recent new product launch activity. The strong top line performance drove increased operating income margins and cash flows. We still have a lot of work to do, but our results clearly suggest that our performance is on track and we expect the ongoing execution of our plan to continue to deliver strong financial performance as we move forward.”

GUIDANCE:

Dentsply Sirona sees FY2020 EPS of $2.55-$2.80, versus the consensus of $2.73. Dentsply Sirona sees FY2020 revenue of $4.1-4.15 billion, versus the consensus of $4.13 billion.

For earnings history and earnings-related data on Dentsply Sirona (XRAY) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• South Plains Financial Inc. (SPFI) Tops Q1 EPS by 6c
• ResMed (RMD) Tops Q3 EPS by 20c